Correlation between change in lung density and lung function parameters in treated alpha-1 protease inhibitor (A1-PI) deficiency Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016
Alpha-1 antitrypsin genotypes and associated inhibitory activity towards neutrophil serine proteinases, in vivo Source: International Congress 2015 – Translational research in respiratory care: new findings Year: 2015
Alpha-1 antitrypsin genotypes and associated inhibitory activity towards neutrophil serine proteinases, in vitro Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015
Pirfenidone, proton pump inhibitor, N acetyl cysteine (PINPOINT) therapy for IPF: Tolerance and safety profile among Indian patients Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012
Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1 -proteinase inhibitor in alpha1 -antitrypsin deficiency Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Differences in training response between patients with alpha-1 antitrypsin deficiency and COPD patients Source: International Congress 2015 – Best abstracts in functional capacity in chronic lung diseases Year: 2015
SPARTA: Efficacy and safety assessment of two regimens of alpha1 -proteinase inhibitor in emphysema due to alpha1 -antitrypsin deficiency Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Inhibition of elastinolytic activity in induced sputum from COPD patients and healthy controls by recombinant alpha 1-antitrypsin (rAAT) and a fusion protein, TAPI Source: Eur Respir J 2004; 24: Suppl. 48, 471s Year: 2004
Blood eosinophils as a biomarker in alpha 1 anti trypsin deficiency Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015
Assessment of A1-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
The effect of posture on ventilation using SLP in healthy subject and patients with Alpha 1 anti-trypsin deficiency (A1AT) Source: International Congress 2014 – Respiratory function: quality and new technologies Year: 2014
Predicting clinical course of alpha 1 anti-trypsin deficiency (AATD) using GOLD 2011 classification Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013
Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003
The effects of endogenous and exogenous vitamin D on the rate of mature elastin degradation in COPD patients Source: International Congress 2016 – New signalling pathways in COPD Year: 2016
LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV1162, a narrow spectrum kinase inhibitor, in healthy subjects and COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
Plant proteinase inhibitor from crataeva tapia (CrataBl) attenuates inflammation and remodelling induced by elastase in mice Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001
Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004